-
Uncategorized1 week ago
Takeda Restructuring Could Push More Than 600 US Staffers Out of Jobs
Takeda’s layoffs include cutting 247 people in Massachusetts. The workforce reduction is meant to help offset investments in areas including a product launch for oral drug...
-
Uncategorized1 week ago
Biotech Mega-Rounder Kailera Seeks IPO
Analysts are cautiously optimistic about an IPO rebound for biopharma. BioSpace is keeping track of companies that seek to trade on the public markets this year.
-
Uncategorized1 week ago
Eli Lilly to pay $115M upfront to Insilico in AI drug discovery deal
Another key player in China’s biotech ecosystem has landed a pharma deal. On Sunday, Eli Lilly and Insilico Medicine announced a drug discovery collaboration, with the...
-
Uncategorized1 week agoSTAT+: Biogen lupus drug improves skin clearance in mid-stage study
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Insilico Medicine signed a large...
-
Uncategorized1 week agoRaw dairy co. refutes connection to E. coli outbreak
Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here. Good morning and happy Monday. I hope you...
-
Uncategorized1 week ago
Merck Pushes Winrevair Past Dose-Response Doubts Into Pivotal Study for Rare Type of Heart Failure
The lack of a dose-response effect could be due to the high number of dropouts in the higher-dose Winrevair arm and the relatively small study population,...
-
Uncategorized1 week ago
As J&J Brings Icotyde to Market, AbbVie Remains Confident in Skyrizi’s Efficacy Edge
AbbVie’s Skyrizi appears to have stronger efficacy than Johnson & Johnson’s newly approved pill Icotyde, as well as a less frequent dosing schedule that patients could...
-
Uncategorized1 week ago
Lilly Grows AI Footprint with Up-to-$2.75B Insilico Collaboration
Eli Lilly and Insilico Medicine are expanding a three-year partnership with a discovery and development collaboration that could generate more than $2.75 billion for the AI-based drug developer, Insilico said Sunday. Lilly has agreed...
-
Uncategorized1 week ago
#AAD26: Sanofi reports underwhelming Phase 3 OX40 data in eczema, second case of Kaposi’s sarcoma
Sanofi on Saturday shared more mixed efficacy results from a Phase 3 atopic dermatitis program for its anti-OX40 ligand monoclonal antibody, further eroding Wall Street’s already...
-
Uncategorized1 week ago
African Trypanosomes Use a Molecular Shredder to Avoid Detection in the Bloodstream
In mammalian hosts, the African trypanosome parasite replicates freely in the bloodstream, despite being fully exposed to the immune system. To do this, the pathogen relies...
Sanofi Bispecific Scores in Asthma, Rhinosinusitis, but Eczema Bet Doesn’t Pay Off
